Evidence map›Paper›PMID 26908758›Full record

Trial reportThe Journal of infectious diseases2016

Periodic Presumptive Treatment for Vaginal Infections May Reduce the Incidence of Sexually Transmitted Bacterial Infections.

Jennifer E Balkus, Lisa E Manhart, Jeannette Lee, Omu Anzala, Joshua Kimani, Jane Schwebke, Juma Shafi, Charles Rivers, Emanuel Kabare, R Scott McClelland

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Sexually transmitted infections · 2019
    Pooled it
  2. Mycoplasma genitalium Infection in Kenyan and US Women.Sexually transmitted diseases · 2018
    Trial
  3. Article
  4. Review
  5. Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data From Sexual Health Clinics in 4 US Regions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. The Female Vaginal Microbiome in Health and Bacterial Vaginosis.Frontiers in cellular and infection microbiology · 2021
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Jennifer E BalkusVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center Department of Global Health.
Lisa E ManhartDepartment of Global Health Department of Epidemiology.
Jeannette LeeDepartment of Biostatistics, University of Arkansas for Medical Sciences, Little Rock.
Omu AnzalaDepartment of Medical Microbiology.
Joshua KimaniUniversity of Nairobi Institute for Tropical and Infectious Diseases, University of Nairobi, Kenya.
Jane SchwebkeDepartment of Medicine, University of Alabama at Birmingham.
Juma ShafiUniversity of Nairobi Institute for Tropical and Infectious Diseases, University of Nairobi, Kenya.
Charles RiversDepartment of Medicine, University of Alabama at Birmingham.
Emanuel KabareUniversity of Nairobi Institute for Tropical and Infectious Diseases, University of Nairobi, Kenya.
R Scott McClellandDepartment of Global Health Department of Medicine, University of Washington, Seattle University of Nairobi Institute for Tropical and Infectious Diseases, University of Nairobi, Kenya.
University of Nairobi · KEUniversity of Alabama at Birmingham · USFred Hutch Cancer Center · USUniversity of Arkansas for Medical Sciences · US

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
Impact of suppressive antimicrobial therapy on the vaginal microbiota and BVR01AI099106 · NIAID · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, RAYMOND SCOTT · 2012 to 2014
$1.8M
NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI099106
6 · The paper itself

Abstract

backgroundBacterial vaginosis (BV) may increase women's susceptibility to sexually transmitted infections (STIs). In a randomized trial of periodic presumptive treatment (PPT) to reduce vaginal infections, we observed a significant reduction in BV. We further assessed the intervention effect on incident Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium infection.

methodsNonpregnant, human immunodeficiency virus-uninfected women from the United States and Kenya received intravaginal metronidazole (750 mg) plus miconazole (200 mg) or placebo for 5 consecutive nights each month for 12 months. Genital fluid specimens were collected every other month. Poisson regression models were used to assess the intervention effect on STI acquisition.

resultsOf 234 women enrolled, 221 had specimens available for analysis. Incidence of any bacterial STI (C. trachomatis, N. gonorrhoeae, or M. genitalium infection) was lower in the intervention arm, compared with the placebo arm (incidence rate ratio [IRR], 0.54; 95% confidence interval [CI], .32-.91). When assessed individually, reductions in STI incidences were similar but not statistically significant (IRRs, 0.50 [95% confidence interval {CI}, .20-1.23] for C. trachomatis infection, 0.56 [95% CI, .19-1.67] for N. gonorrhoeae infection, and 0.66 [95% CI, .38-1.15] for M. genitalium infection).

conclusionsIn addition to reducing BV, this PPT intervention may also reduce the risk of bacterial STI among women. Because BV is highly prevalent, often persists, and frequently recurs after treatment, interventions that reduce BV over extended periods could play a role in decreasing STI incidence globally.

Indexed as

AdultAnti-Infective AgentsChlamydia InfectionsChlamydia trachomatisDrug Therapy, CombinationFemaleGonorrheaHumansIncidenceKenyaMetronidazoleMiconazoleMycoplasma genitaliumMycoplasma InfectionsNeisseria gonorrhoeaePre-Exposure ProphylaxisAnti-Infective AgentsMetronidazoleMiconazolebacterial vaginosisChlamydia trachomatisMycoplasma genitaliumNeisseria gonorrhoeaeperiodic presumptive treatmentvaginal health interventions

Identifiers

PMID26908758
PMCPMC4878720
OpenAlexW2252720940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.